D.E. Shaw & Co
TBIO

D.E. Shaw & Co’s Telesis Bio, Inc. Common Stock TBIO Stock Holding History

D.E. Shaw & Co’s Portfolio TBIO Stock Details TBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-2,195
Closed -$66K – 5218
2022
Q3 		$66K Buy
+2,195
New +$77.3K ﹤0.01% 4653
2021
Q4 		– Sell
-1,108
Closed -$222K – 5788
2021
Q3 		$222K Buy
+1,108
New +$281K ﹤0.01% 4518

Other funds holding TBIO

NV
Northpond Ventures Bethesda, Maryland $43.7M AUM 27.27% 1-Year Est. Return
PCM
Penn Capital Management Philadelphia, Pennsylvania $1.58B AUM 81.2% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
PM
Penbrook Management New York $157M AUM 46.57% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

D.E. Shaw & Co's TBIO Position: Q4 2022 in Review

D.E. Shaw & Co sold out of Telesis Bio, Inc. Common Stock (TBIO) in Q4 2022, closing a stake of 2,195 shares — an estimated $66K sold.

D.E. Shaw & Co first reported a position in TBIO in Q3 2021 and held it in 2 quarters. The position peaked at $222K in Q3 2021. 24 funds tracked by Wall St. Rank hold TBIO as of Q4 2022.

  • D.E. Shaw & Co reported no remaining Telesis Bio, Inc. Common Stock position as of Q4 2022 after selling out during the quarter.
  • D.E. Shaw & Co sold 2,195 Telesis Bio, Inc. Common Stock shares in Q4 2022, an estimated $66K.
  • D.E. Shaw & Co first reported a position in Telesis Bio, Inc. Common Stock in Q3 2021 and held it in 2 quarters.
  • D.E. Shaw & Co's Telesis Bio, Inc. Common Stock position peaked at $222K in Q3 2021.
  • 24 funds tracked by Wall St. Rank held Telesis Bio, Inc. Common Stock as of Q4 2022.

Based on D.E. Shaw & Co's 13F filing for Q4 2022, filed 14 Feb 2023.